SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla rises on the bourses

23 Mar 2020 Evaluate

Cipla is currently trading at Rs. 397.30, up by 3.70 points or 0.94% from its previous closing of Rs. 393.60 on the BSE.

The scrip opened at Rs. 385.00 and has touched a high and low of Rs. 432.00 and Rs. 372.30 respectively. So far 96739 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 585.50 on 27-May-2019 and a 52 week low of Rs. 356.75 on 13-Mar-2020.

Last one week high and low of the scrip stood at Rs. 432.00 and Rs. 363.85 respectively. The current market cap of the company is Rs. 30721.60 crore.

The promoters holding in the company stood at 36.68%, while Institutions and Non-Institutions held 41.17% and 22.16% respectively.

Hyderabad-based CSIR-Indian Institute of Chemical Technology (IICT) has partnered with Cipla to work on development of anti- viral drugs to contain COVID-19. Research on anti-viral drugs has been on throughout the world for long and many companies have developed molecules having anti-viral properties. But due to lack of demand, these molecules were not widely marketed. However, the CSIR-IICT decided to work on three such molecules -- remdesivir, favipiravir and baloxavir.

Cipla urged the IICT director S Chandrasekhar to start work on these molecules on an immediate basis. Cipla would upscale the process on the basis of know-how given by CSIR-IICT.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

 

Cipla Share Price

1365.25 31.70 (2.38%)
06-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1850.40
Dr. Reddys Lab 1310.50
Cipla 1365.25
Zydus Lifesciences 939.10
Lupin 2442.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×